VahatiCor Raises $23 Million Series B to Advance Device Therapy for Coronary Microvascular Dysfunction
VahatiCor, a medical technology company headquartered in Santa Clara, California, has closed a $23 million Series B financing round to accelerate the clinical development of its novel therapy for Coronary Microvascular Dysfunction (CMD), a condition that causes persistent chest pain and ischemic symptoms despite the absence of obstructive coronary artery disease. The oversubscribed round highlights growing investor confidence in the company’s approach to addressing a significant and underserved cardiovascular condition.
The Series B round was led by S3 Ventures, with participation from Intuitive Ventures and a strategic investor. The new capital is intended to support advancement of VahatiCor’s clinical programs, continued engineering development, and preparation for subsequent regulatory and clinical milestones as the company progresses toward larger-scale studies.
VahatiCor is focused on developing device-based solutions for patients with CMD, a population that represents millions of individuals worldwide and for whom treatment options remain limited. Many CMD patients experience chronic angina and reduced quality of life, and existing pharmaceutical therapies often fail to adequately control symptoms. This unmet need has driven interest in interventional approaches that target the underlying physiological mechanisms of the disease.
The company’s lead product is the A-FLUX® Reducer System, a coronary sinus reducer designed to improve myocardial perfusion by creating a controlled narrowing of the coronary sinus. By redistributing blood flow within the heart, the device aims to alleviate ischemic symptoms in patients with CMD. The system features a self-expanding, repositionable design intended to support procedural flexibility and safety during implantation.
Proceeds from the Series B financing are being used to advance VahatiCor’s SERRA-I early feasibility study, which is evaluating the safety and performance of the A-FLUX Reducer System in patients with persistent symptomatic CMD. The study represents a key step in generating clinical evidence to support broader trials and future regulatory submissions. In addition to supporting clinical enrollment, the funding will enable further refinement of the device and expansion of the company’s engineering and development capabilities.
Leadership at VahatiCor has stated that the successful financing reflects validation of both the company’s technology and its strategic focus on CMD. The backing of experienced healthcare investors is expected to provide not only capital but also strategic guidance as the company navigates the complexities of clinical development and prepares for potential commercialization.
CMD disproportionately affects women and is increasingly recognized as a serious cardiovascular condition associated with higher rates of adverse cardiac events when coronary flow reserve is impaired. Despite its prevalence, awareness and treatment options have lagged behind those for obstructive coronary artery disease. VahatiCor’s approach seeks to fill this gap by offering a minimally invasive therapy specifically designed for this patient population.
S3 Ventures, which led the financing, is a venture capital firm with a long track record of investing in technology and healthcare companies at critical growth stages. Its involvement signals confidence in VahatiCor’s ability to translate its clinical vision into a scalable medical solution. Intuitive Ventures, the venture arm affiliated with Intuitive Surgical, brings expertise in minimally invasive medical technologies and supports companies advancing innovative interventional care.
With the Series B funding secured, VahatiCor plans to continue expanding its clinical footprint, strengthening its development team, and laying the groundwork for future pivotal studies. The company’s progress comes amid increasing interest from investors and clinicians in device-based therapies that address complex cardiovascular conditions through targeted, minimally invasive interventions.
The latest financing marks an important milestone for VahatiCor as it works to bring a new therapeutic option to patients living with CMD. Supported by its investors and advancing through early clinical evaluation, the company is positioning itself to play a meaningful role in the future of cardiovascular care by addressing a long-standing unmet medical need.
